Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Non-Current Deferred Tax Liability (2021 - 2023)

Zentalis Pharmaceuticals has reported Non-Current Deferred Tax Liability over the past 3 years, most recently at $10.3 million for Q4 2023.

  • For Q4 2023, Non-Current Deferred Tax Liability rose 1112.08% year-over-year to $10.3 million; the TTM value through Dec 2023 reached $10.3 million, up 1112.08%, while the annual FY2023 figure was $10.3 million, 1112.08% up from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2023 was $10.3 million at Zentalis Pharmaceuticals, up from $756000.0 in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $10.3 million in Q4 2023 and troughed at $756000.0 in Q1 2023.
  • A 3-year average of $2.5 million and a median of $1.3 million in 2022 define the central range for Non-Current Deferred Tax Liability.
  • On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 1112.08% in 2023 and fell as far as 51.16% in 2023.
  • Year by year, Non-Current Deferred Tax Liability stood at $1.6 million in 2021, then plummeted by 47.41% to $853000.0 in 2022, then skyrocketed by 1112.08% to $10.3 million in 2023.
  • Business Quant data shows Non-Current Deferred Tax Liability for ZNTL at $10.3 million in Q4 2023, $756000.0 in Q1 2023, and $853000.0 in Q4 2022.